This study is in progress, not accepting new patients
Study Of NOVOTTF-200A In Bevacizumab-Naive Subjects With Recurrent Grade III Malignant Astrocytoma
Summary
- Eligibility
- for people ages 22 years and up (full criteria)
- Location
- at UC Irvine
- Dates
- study startedcompletion around
- Principal Investigator
- by Daniela Bota, MD (uci)
Description
Summary
Official Title
Details
Keywords
Eligibility
Location
Lead Scientist at University of California Health
- Daniela Bota, MD (uci)
Professor, Neurology, School of Medicine. Authored (or co-authored) 98 research publications
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Daniela A. Bota
- ID
- NCT03450850
- Study Type
- Interventional
- Participants
- Expecting 34 study participants
- Last Updated